Concepedia

Author

Luigi Portella

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"ORCID

Also Known As

L P Llamocca Portella, L. Portella, Luigi Portella, Portella, Luigi

133

Publications

1.6K

Citations

22

H-Index

37

Concepts

All Affiliations

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"University of Naples Federico IIUniversity of Campania "Luigi Vanvitelli"Federico II University HospitalCornell University
LP

About

Luigi Portella is an author at Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" specializing in medicine, cell biology, and drug discovery.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

265

2

Cell Biology

6

6

206

3

Biochemistry

3

3

74

4

Engineering

1

1

14

5

Natural Sciences

1

1

27

Luigi Portella

×

30

Publications

1.4K

Citations

20

H-Index

YearCitations

Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer

Maria Thadani‐Mulero, Luigi Portella, Shihua Sun,

Cancer Research

2014

259

Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY

Scott T. Tagawa, Emmanuel S. Antonarakis, Ada Gjyrezi,

Clinical Cancer Research

2018

113

Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1

Crescenzo D’Alterio, Maria Buoncervello, Caterina Ieranò,

Journal of Experimental & Clinical Cancer Research

2019

105

Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases

Luigi Portella, Rosa Maria Vitale, Stefania De Luca,

PLoS ONE

2013

85

Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer

Emmanuel S. Antonarakis, Scott T. Tagawa, Giuseppe Galletti,

Journal of Clinical Oncology

2017

81

Concomitant CXCR4 and CXCR7 Expression Predicts Poor Prognosis in Renal Cancer

Crescenzo D’Alterio, Claudia Consales, Maria Neve Polimeno,

Current Cancer Drug Targets

2010

79

Differential role of CD133 and CXCR4 in renal cell carcinoma

Crescenzo D’Alterio, Luca Cindolo, Luigi Portella,

Cell Cycle

2010

68

Regulatory <scp>T</scp> cells, interleukin ( <scp>IL</scp> )‐6, <scp>IL</scp> ‐8, <scp>V</scp> ascular endothelial growth factor ( <scp>VEGF</scp> ), <scp>CXC</scp> L10, <scp>CXC</scp> L11, epidermal growth factor ( <scp>EGF</scp> ) and hepatocyte growth factor ( <scp>HGF</scp> ) as surrogate markers of host immunity in patients with renal cell carcinoma

Marianeve Polimeno, Maria Napolitano, Susan Costantini,

British Journal of Urology

2013

66

In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies

Caterina Ieranò, Dario Righelli, Crescenzo D’Alterio,

Journal for ImmunoTherapy of Cancer

2022

60

Circulating Tumor Cells in Prostate Cancer Diagnosis and Monitoring: An Appraisal of Clinical Potential

Giuseppe Galletti, Luigi Portella, Scott T. Tagawa,

Molecular Diagnosis & Therapy

2014

59

Page 1